Signaling Pathways Driving Aberrant Splicing in Cancer Cells
Abstract
:1. Introduction
2. Deregulation of Alternative Splicing by Oncogene-Driven Signaling
2.1. Oncogenic Stimulation of the RAS/RAF/ERK Pathway
2.2. Stimulation of the PI3K/AKT Pathway
2.3. Stimulation of the Wnt Pathway
2.4. Other Pathways Activated in Proliferating Cells
3. Deregulation of Alternative Splicing by Tumor Microenvironment-Derived Signaling
3.1. Soluble Factors
3.1.1. Growth Factor Signaling
3.1.2. Immune Cell or Inflammation-Derived Signals
3.2. Metabolic Stress Conditions
3.2.1. Hypoxia
3.2.2. Oxidative Stress
3.2.3. Osmotic Stress
3.2.4. Genotoxic Stress
3.3. Extracellular Matrix-Derived Signals
4. Concluding Remarks
Supplementary Materials
Acknowledgments
Conflicts of Interest
References
- Matera, A.G.; Wang, Z. A day in the life of the spliceosome. Nat. Rev. Mol. Cell Biol. 2014, 15, 108–121. [Google Scholar] [CrossRef] [PubMed]
- Wahl, M.C.; Will, C.L.; Lührmann, R. The Spliceosome: Design principles of a dynamic RNP machine. Cell 2009, 136, 701–718. [Google Scholar] [CrossRef] [PubMed]
- Chen, M.; Manley, J.L. Mechanisms of alternative splicing regulation: Insights from molecular and genomics approaches. Nat. Rev. Mol. Cell Biol. 2009, 10, 741–754. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.; Rio, D.C. Mechanisms and regulation of alternative pre-mRNA splicing. Annu. Rev. Biochem. 2015, 84, 291–323. [Google Scholar] [CrossRef] [PubMed]
- Nilsen, T.W.; Graveley, B.R. Expansion of the eukaryotic proteome by alternative splicing. Nature 2010, 463, 457–463. [Google Scholar] [CrossRef] [PubMed]
- Pan, Q.; Shai, O.; Lee, L.J.; Frey, B.J.; Blencowe, B.J. Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nat. Genet. 2008, 40, 1413–1415. [Google Scholar] [CrossRef] [PubMed]
- Wang, E.T.; Sandberg, R.; Luo, S.; Khrebtukova, I.; Zhang, L.; Mayr, C.; Kingsmore, S.F.; Schroth, G.P.; Burge, C.B. Alternative isoform regulation in human tissue transcriptomes. Nature 2008, 456, 470–476. [Google Scholar] [CrossRef] [PubMed]
- Scotti, M.M.; Swanson, M.S. RNA mis-splicing in disease. Nat. Rev. Genet. 2015, 17, 19–32. [Google Scholar] [CrossRef] [PubMed]
- Buljan, M.; Chalancon, G.; Eustermann, S.; Wagner, G.P.; Fuxreiter, M.; Bateman, A.; Babu, M.M. Tissue-specific splicing of disordered segments that embed binding motifs rewires protein interaction networks. Mol. Cell 2012, 46, 871–883. [Google Scholar] [CrossRef] [PubMed]
- Ellis, J.D.; Barrios-Rodiles, M.; Colak, R.; Irimia, M.; Kim, T.; Calarco, J.A.; Wang, X.; Pan, Q.; O’Hanlon, D.; Kim, P.M.; et al. Tissue-specific alternative splicing remodels protein-protein interaction networks. Mol. Cell 2012, 46, 884–892. [Google Scholar] [CrossRef] [PubMed]
- Weatheritt, R.J.; Sterne-Weiler, T.; Blencowe, B.J. The ribosome-engaged landscape of alternative splicing. Nat. Struct. Mol. Biol. 2016, 23, 1117–1123. [Google Scholar] [CrossRef] [PubMed]
- Braunschweig, U.; Barbosa-Morais, N.L.; Pan, Q.; Nachman, E.N.; Alipanahi, B.; Gonatopoulos-Pournatzis, T.; Frey, B.; Irimia, M.; Blencowe, B.J. Widespread intron retention in mammals functionally tunes transcriptomes. Genome Res. 2014, 24, 1774–1786. [Google Scholar] [CrossRef] [PubMed]
- Lareau, L.F.; Inada, M.; Green, R.E.; Wengrod, J.C.; Brenner, S.E. Unproductive splicing of SR genes associated with highly conserved and ultraconserved DNA elements. Nature 2007, 446, 926–929. [Google Scholar] [CrossRef] [PubMed]
- Ni, J.Z.; Grate, L.; Donohue, J.P.; Preston, C.; Nobida, N.; O’Brien, G.; Shiue, L.; Clark, T.A.; Blume, J.E.; Ares, M. Ultraconserved elements are associated with homeostatic control of splicing regulators by alternative splicing and nonsense-mediated decay. Genes Dev. 2007, 21, 708–718. [Google Scholar] [CrossRef] [PubMed]
- Mayr, C.; Bartel, D.P. Widespread shortening of 3′UTRs by alternative cleavage and polyadenylation activates oncogenes in cancer cells. Cell 2009, 138, 673–684. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ogorodnikov, A.; Kargapolova, Y.; Danckwardt, S. Processing and transcriptome expansion at the mRNA 3′ end in health and disease: Finding the right end. Pflüg. Arch. Eur. J. Physiol. 2016, 468, 993–1012. [Google Scholar] [CrossRef] [PubMed]
- Barash, Y.; Calarco, J.A.; Gao, W.; Pan, Q.; Wang, X.; Shai, O.; Blencowe, B.J.; Frey, B.J. Deciphering the splicing code. Nature 2010, 465, 53–59. [Google Scholar] [CrossRef] [PubMed]
- Castle, J.C.; Zhang, C.; Shah, J.K.; Kulkarni, A.V.; Kalsotra, A.; Cooper, T.A.; Johnson, J.M. Expression of 24,426 human alternative splicing events and predicted cis regulation in 48 tissues and cell lines. Nat. Genet. 2008, 40, 1416–1425. [Google Scholar] [CrossRef] [PubMed]
- Gallego-Paez, L.M.; Bordone, M.C.; Leote, A.C.; Saraiva-Agostinho, N.; Ascensão-Ferreira, M.; Barbosa-Morais, N.L. Alternative splicing: The pledge, the turn, and the prestige: The key role of alternative splicing in human biological systems. Hum. Genet. 2017, 136, 1015–1042. [Google Scholar] [CrossRef] [PubMed]
- Grosso, A.R.; Gomes, A.Q.; Barbosa-Morais, N.L.; Caldeira, S.; Thorne, N.P.; Grech, G.; von Lindern, M.; Carmo-Fonseca, M. Tissue-specific splicing factor gene expression signatures. Nucleic Acids Res. 2008, 36, 4823–4832. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- David, C.J.; Manley, J.L. Alternative pre-mRNA splicing regulation in cancer: Pathways and programs unhinged. Genes Dev. 2010, 24, 2343–2364. [Google Scholar] [CrossRef] [PubMed]
- Srebrow, A.; Kornblihtt, A.R. The connection between splicing and cancer. J. Cell Sci. 2006, 119, 2635–2641. [Google Scholar] [CrossRef] [PubMed]
- Venables, J.P. Unbalanced alternative splicing and its significance in cancer. BioEssays 2006, 28, 378–386. [Google Scholar] [CrossRef] [PubMed]
- Abdel-Wahab, O.; Levine, R. The Spliceosome as an indicted conspirator in myeloid malignancies. Cancer Cell 2011, 20, 420–422. [Google Scholar] [CrossRef] [PubMed]
- Scott, L.M.; Rebel, V.I. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. J. Natl. Cancer Inst. 2013, 105, 1540–1549. [Google Scholar] [CrossRef] [PubMed]
- Dvinge, H.; Kim, E.; Abdel-Wahab, O.; Bradley, R.K. RNA splicing factors as oncoproteins and tumor suppressors. Nat. Rev. Cancer 2016, 16, 413–430. [Google Scholar] [CrossRef] [PubMed]
- Madan, V.; Kanojia, D.; Li, J.; Okamoto, R.; Sato-Otsubo, A.; Kohlmann, A.; Sanada, M.; Grossmann, V.; Sundaresan, J.; Shiraishi, Y.; et al. Aberrant splicing of U12-type introns is the hallmark of ZRSR2 mutant myelodysplastic syndrome. Nat. Commun. 2015, 6, 6042. [Google Scholar] [CrossRef] [PubMed]
- Ghigna, C.; Valacca, C.; Biamonti, G. Alternative splicing and tumor progression. Curr. Genom. 2008, 9, 556–570. [Google Scholar] [CrossRef] [PubMed]
- Ghigna, C.; Moroni, M.; Porta, C.; Riva, S.; Biamonti, G. Altered expression of heterogenous nuclear ribonucleoproteins and SR factors in human colon adenocarcinomas. Cancer Res. 1998, 58, 5818–5824. [Google Scholar] [PubMed]
- Grosso, A.R.; Martins, S.; Carmo-Fonseca, M. The emerging role of splicing factors in cancer. EMBO Rep. 2008, 9, 1087–1093. [Google Scholar] [CrossRef] [PubMed]
- Sveen, A.; Kilpinen, S.; Ruusulehto, A.; Lothe, R.A.; Skotheim, R.I. Aberrant RNA splicing in cancer; expression changes and driver mutations of splicing factor genes. Oncogene 2016, 35, 2413–2427. [Google Scholar] [CrossRef] [PubMed]
- Karni, R.; de Stanchina, E.; Lowe, S.W.; Sinha, R.; Mu, D.; Krainer, A.R. The gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat. Struct. Mol. Biol. 2007, 14, 185–193. [Google Scholar] [CrossRef] [PubMed]
- Diederichs, S.; Bartsch, L.; Berkmann, J.C.; Fröse, K.; Heitmann, J.; Hoppe, C.; Iggena, D.; Jazmati, D.; Karschnia, P.; Linsenmeier, M.; et al. The dark matter of the cancer genome: Aberrations in regulatory elements, untranslated regions, splice sites, non-coding RNA and synonymous mutations. EMBO Mol. Med. 2016, 8, 442–457. [Google Scholar] [CrossRef] [PubMed]
- Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell 2011, 144, 646–674. [Google Scholar] [CrossRef] [PubMed]
- Logue, J.S.; Morrison, D.K. Complexity in the signaling network: Insights from the use of targeted inhibitors in cancer therapy. Genes Dev. 2012, 26, 641–650. [Google Scholar] [CrossRef] [PubMed]
- Hollander, D.; Donyo, M.; Atias, N.; Mekahel, K.; Melamed, Z.; Yannai, S.; Lev-Maor, G.; Shilo, A.; Schwartz, S.; Barshack, I.; et al. A network-based analysis of colon cancer splicing changes reveals a tumorigenesis-favoring regulatory pathway emanating from ELK1. Genome Res. 2016, 26, 541–553. [Google Scholar] [CrossRef] [PubMed]
- Takahashi, H.; Nishimura, J.; Kagawa, Y.; Kano, Y.; Takahashi, Y.; Wu, X.; Hiraki, M.; Hamabe, A.; Konno, M.; Haraguchi, N.; et al. Significance of polypyrimidine tract-binding protein 1 expression in colorectal cancer. Mol. Cancer Ther. 2015, 14, 1705–1716. [Google Scholar] [CrossRef] [PubMed]
- Matter, N.; Herrlich, P.; König, H. Signal-dependent regulation of splicing via phosphorylation of Sam68. Nature 2002, 420, 691–695. [Google Scholar] [CrossRef] [PubMed]
- Weg-Remers, S.; Ponta, H.; Herrlich, P.; König, H. Regulation of alternative pre-mRNA splicing by the ERK MAP-kinase pathway. EMBO J. 2001, 20, 4194–4203. [Google Scholar] [CrossRef] [PubMed]
- Valacca, C.; Bonomi, S.; Buratti, E.; Pedrotti, S.; Baralle, F.E.; Sette, C.; Ghigna, C.; Biamonti, G. Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene. J. Cell Biol. 2010, 191, 87–99. [Google Scholar] [CrossRef] [PubMed]
- Al-Ayoubi, A.M.; Zheng, H.; Liu, Y.; Bai, T.; Eblen, S.T. Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion. Mol. Cell Biol. 2012, 32, 2880–2893. [Google Scholar] [CrossRef] [PubMed]
- Vecchione, L.; Gambino, V.; Raaijmakers, J.; Schlicker, A.; Fumagalli, A.; Russo, M.; Villanueva, A.; Beerling, E.; Bartolini, A.; Mollevi, D.G.; et al. A vulnerability of a subset of colon cancers with potential clinical utility. Cell 2016, 165, 317–330. [Google Scholar] [CrossRef] [PubMed]
- Saitoh, N.; Sakamoto, C.; Hagiwara, M.; Agredano-Moreno, L.T.; Jimenez-Garcia, L.F.; Nakao, M. The distribution of phosphorylated SR proteins and alternative splicing are regulated by RANBP2. Mol. Biol. Cell 2012, 23, 1115–1128. [Google Scholar] [CrossRef] [PubMed]
- Shilo, A.; Ben Hur, V.; Denichenko, P.; Stein, I.; Pikarsky, E.; Rauch, J.; Kolch, W.; Zender, L.; Karni, R. Splicing factor hnRNP A2 activates the Ras-MAPK-ERK pathway by controlling A-Raf splicing in hepatocellular carcinoma development. RNA 2014, 20, 505–515. [Google Scholar] [CrossRef] [PubMed]
- De Miguel, F.J.; Sharma, R.D.; Pajares, M.J.; Montuenga, L.M.; Rubio, A.; Pio, R. Identification of alternative splicing events regulated by the oncogenic factor SRSF1 in lung cancer. Cancer Res. 2014, 74, 1105–1115. [Google Scholar] [CrossRef] [PubMed]
- Karakas, B.; Bachman, K.E.; Park, B.H. Mutation of the PIK3CA oncogene in human cancers. Br. J. Cancer 2006, 94, 455–459. [Google Scholar] [CrossRef] [PubMed]
- Blaustein, M.; Pelisch, F.; Tanos, T.; Muñoz, M.J.; Wengier, D.; Quadrana, L.; Sanford, J.R.; Muschietti, J.P.; Kornblihtt, A.R.; Cáceres, J.F.; et al. Concerted regulation of nuclear and cytoplasmic activities of SR proteins by AKT. Nat. Struct. Mol. Biol. 2005, 12, 1037–1044. [Google Scholar] [CrossRef] [PubMed]
- Zhou, Z.; Qiu, J.; Liu, W.; Zhou, Y.; Plocinik, R.M.; Li, H.; Hu, Q.; Ghosh, G.; Adams, J.A.; Rosenfeld, M.G.; et al. The Akt-SRPK-SR axis constitutes a major pathway in transducing EGF signaling to regulate alternative splicing in the nucleus. Mol. Cell 2012, 47, 422–433. [Google Scholar] [CrossRef] [PubMed]
- Voukkalis, N.; Koutroumani, M.; Zarkadas, C.; Nikolakaki, E.; Vlassi, M.; Giannakouros, T. SRPK1 and Akt Protein Kinases phosphorylate the RS domain of Lamin B receptor with distinct specificity: A combined biochemical and in silico approach. PLoS ONE 2016, 11, e0154198. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, G.; Adams, J.A. Phosphorylation mechanism and structure of serine-arginine protein kinases. FEBS J. 2011, 278, 587–597. [Google Scholar] [CrossRef] [PubMed]
- Ngo, J.C.K.; Chakrabarti, S.; Ding, J.-H.; Velazquez-Dones, A.; Nolen, B.; Aubol, B.E.; Adams, J.A.; Fu, X.-D.; Ghosh, G. Interplay between SRPK and Clk/Sty kinases in phosphorylation of the splicing factor ASF/SF2 is regulated by a docking motif in ASF/SF2. Mol. Cell 2005, 20, 77–89. [Google Scholar] [CrossRef] [PubMed]
- Shultz, J.C.; Goehe, R.W.; Wijesinghe, D.S.; Murudkar, C.; Hawkins, A.J.; Shay, J.W.; Minna, J.D.; Chalfant, C.E. Alternative splicing of caspase 9 is modulated by the phosphoinositide 3-kinase/Akt pathway via phosphorylation of SRp30a. Cancer Res. 2010, 70, 9185–9196. [Google Scholar] [CrossRef] [PubMed]
- Goehe, R.W.; Shultz, J.C.; Murudkar, C.; Usanovic, S.; Lamour, N.F.; Massey, D.H.; Zhang, L.; Camidge, D.R.; Shay, J.W.; Minna, J.D.; et al. HnRNP L regulates the tumorigenic capacity of lung cancer xenografts in mice via caspase-9 pre-mRNA processing. J. Clin. Investig. 2010, 120, 3923–3939. [Google Scholar] [CrossRef] [PubMed]
- Vu, N.T.; Park, M.A.; Shultz, J.C.; Goehe, R.W.; Hoeferlin, L.A.; Shultz, M.D.; Smith, S.A.; Lynch, K.W.; Chalfant, C.E. HnRNP U enhances caspase-9 splicing and is modulated by AKT-dependent phosphorylation of hnRNP L. J. Biol. Chem. 2013, 288, 8575–8584. [Google Scholar] [CrossRef] [PubMed]
- Cornu, M.; Albert, V.; Hall, M.N. MTOR in aging, metabolism, and cancer. Curr. Opin. Genet. Dev. 2013, 23, 53–62. [Google Scholar] [CrossRef] [PubMed]
- Lee, G.; Zheng, Y.; Cho, S.; Jang, C.; England, C.; Dempsey, J.M.; Yu, Y.; Liu, X.; He, L.; Cavaliere, P.M.; et al. Post-transcriptional regulation of de novo lipogenesis by mTORC1-S6K1-SRPK2 signaling. Cell 2017, 171, 1545–1558. [Google Scholar] [CrossRef] [PubMed]
- Yea, S.; Narla, G.; Zhao, X.; Garg, R.; Tal–Kremer, S.; Hod, E.; Villanueva, A.; Loke, J.; Tarocchi, M.; Akita, K.; et al. Ras promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular carcinoma. Gastroenterology 2008, 134, 1521–1531. [Google Scholar] [CrossRef] [PubMed]
- Jiang, K.; Patel, N.A.; Watson, J.E.; Apostolatos, H.; Kleiman, E.; Hanson, O.; Hagiwara, M.; Cooper, D.R. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCβII messenger ribonucleic acid. Endocrinology 2009, 150, 2087–2097. [Google Scholar] [CrossRef] [PubMed]
- Patel, N.A.; Kaneko, S.; Apostolatos, H.S.; Bae, S.S.; Watson, J.E.; Davidowitz, K.; Chappell, D.S.; Birnbaum, M.J.; Cheng, J.Q.; Cooper, D.R. Molecular and genetic studies imply Akt-mediated signaling promotes protein kinase CβII alternative splicing via phosphorylation of serine/arginine-rich splicing factor SRp40. J. Biol. Chem. 2005, 280, 14302–14309. [Google Scholar] [CrossRef] [PubMed]
- Gökmen-Polar, Y.; Murray, N.R.; Velasco, M.A.; Gatalica, Z.; Fields, A.P. Elevated protein kinase C βII is an early promotive event in colon carcinogenesis. Cancer Res. 2001, 61, 1375–1381. [Google Scholar] [PubMed]
- Zhan, T.; Rindtorff, N.; Boutros, M. Wnt signaling in cancer. Oncogene 2017, 36, 1461–1473. [Google Scholar] [CrossRef] [PubMed]
- Gonçalves, V.; Matos, P.; Jordan, P. The β-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression. RNA 2008, 14, 2538–2549. [Google Scholar] [CrossRef] [PubMed]
- Gonçalves, V.; Matos, P.; Jordan, P. Antagonistic SR proteins regulate alternative splicing of tumor-related Rac1b downstream of the PI3-kinase and Wnt pathways. Hum. Mol. Genet. 2009, 18, 3696–3707. [Google Scholar] [CrossRef] [PubMed]
- Matos, P.; Oliveira, C.; Velho, S.; Gonçalves, V.; da Costa, L.T.; Moyer, M.P.; Seruca, R.; Jordan, P. B-RafV600E cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 2008, 135, 899–906. [Google Scholar] [CrossRef] [PubMed]
- Gonçalves, V.; Henriques, A.; Pereira, J.; Neves Costa, A.; Moyer, M.P.; Moita, L.F.; Gama-Carvalho, M.; Matos, P.; Jordan, P. Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA 2014, 20, 474–482. [Google Scholar] [CrossRef] [PubMed]
- Thorsen, K.; Mansilla, F.; Schepeler, T.; Øster, B.; Rasmussen, M.H.; Dyrskjøt, L.; Karni, R.; Akerman, M.; Krainer, A.R.; Laurberg, S.; et al. Alternative splicing of SLC39A14 in colorectal cancer is regulated by the Wnt pathway. Mol. Cell Proteom. 2011, 10, M110.002998. [Google Scholar] [CrossRef] [PubMed]
- Hernández, F.; Pérez, M.; Lucas, J.J.; Mata, A.M.; Bhat, R.; Avila, J. Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35. Implications for Alzheimer’s disease. J. Biol. Chem. 2004, 279, 3801–3806. [Google Scholar] [CrossRef] [PubMed]
- Heyd, F.; Lynch, K.W. Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol. Cell 2010, 40, 126–137. [Google Scholar] [CrossRef] [PubMed]
- Shinde, M.Y.; Sidoli, S.; Kulej, K.; Mallory, M.J.; Radens, C.M.; Reicherter, A.L.; Myers, R.L.; Barash, Y.; Lynch, K.W.; Garcia, B.A.; et al. Phosphoproteomics reveals that glycogen synthase kinase-3 phosphorylates multiple splicing factors and is associated with alternative splicing. J. Biol. Chem. 2017, 292, 18240–18255. [Google Scholar] [CrossRef] [PubMed]
- Aguilera, O.; Muñoz-Sagastibelza, M.; Torrejón, B.; Borrero-Palacios, A.; del Puerto-Nevado, L.; Martínez-Useros, J.; Rodriguez-Remirez, M.; Zazo, S.; García, E.; Fraga, M.; et al. Vitamin C uncouples the Warburg metabolic switch in KRAS mutant colon cancer. Oncotarget 2016, 7, 47954–47965. [Google Scholar] [CrossRef] [PubMed]
- Caretta, A.; Mucignat-Caretta, C. Protein kinase a in cancer. Cancers 2011, 3, 913–926. [Google Scholar] [CrossRef] [PubMed]
- Xie, J.; Lee, J.-A.; Kress, T.L.; Mowry, K.L.; Black, D.L. Protein kinase A phosphorylation modulates transport of the polypyrimidine tract-binding protein. Proc. Natl. Acad. Sci. USA 2003, 100, 8776–8781. [Google Scholar] [CrossRef] [PubMed]
- Sakamoto, Y.; Yoshida, M.; Semba, K.; Hunter, T. Inhibition of the DNA-binding and transcriptional repression activity of the Wilms’ tumor gene product, WT1, by cAMP-dependent protein kinase-mediated phosphorylation of Ser-365 and Ser-393 in the zinc finger domain. Oncogene 1997, 15, 2001–2012. [Google Scholar] [CrossRef] [PubMed]
- Yang, L.; Han, Y.; Saurez Saiz, F.; Minden, M.D. A tumor suppressor and oncogene: The WT1 story. Leukemia 2007, 21, 868–876. [Google Scholar] [PubMed]
- Amin, E.M.; Oltean, S.; Hua, J.; Gammons, M.V.R.; Hamdollah-Zadeh, M.; Welsh, G.I.; Cheung, M.-K.; Ni, L.; Kase, S.; Rennel, E.S.; et al. WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer Cell 2011, 20, 768–780. [Google Scholar] [CrossRef] [PubMed]
- Mylonis, I.; Giannakouros, T. Protein kinase CK2 phosphorylates and activates the SR protein-specific kinase 1. Biochem. Biophys. Res. Commun. 2003, 301, 650–656. [Google Scholar] [CrossRef]
- Trembley, J.H.; Wang, G.; Unger, G.; Slaton, J.; Ahmed, K. Protein Kinase CK2 in Health and Disease: CK2: A key player in cancer biology. Cell. Mol. Life Sci. 2009, 66, 1858–1867. [Google Scholar] [CrossRef] [PubMed]
- Aung, C.S.; Ye, W.; Plowman, G.; Peters, A.A.; Monteith, G.R.; Roberts-Thomson, S.J. Plasma membrane calcium ATPase 4 and the remodeling of calcium homeostasis in human colon cancer cells. Carcinogenesis 2009, 30, 1962–1969. [Google Scholar] [CrossRef] [PubMed]
- Monteith, G.R.; Davis, F.M.; Roberts-Thomson, S.J. Calcium channels and pumps in cancer: Changes and consequences. J. Biol. Chem. 2012, 287, 31666–31673. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.; Hai, Y.; Liu, G.; Fang, T.; Kung, S.K.P.; Xie, J. The heterogeneous nuclear ribonucleoprotein L is an essential component in the Ca2+/calmodulin-dependent protein kinase IV-regulated alternative splicing through cytidine-adenosine repeats. J. Biol. Chem. 2009, 284, 1505–1513. [Google Scholar] [CrossRef] [PubMed]
- Liu, G.; Razanau, A.; Hai, Y.; Yu, J.; Sohail, M.; Lobo, V.G.; Chu, J.; Kung, S.K.P.; Xie, J. A conserved serine of heterogeneous nuclear ribonucleoprotein L (hnRNP L) mediates depolarization-regulated alternative splicing of potassium channels. J. Biol. Chem. 2012, 287, 22709–22716. [Google Scholar] [CrossRef] [PubMed]
- Bissell, M.J.; Hines, W.C. Why don’t we get more cancer? A proposed role of the microenvironment in restraining cancer progression. Nat. Med. 2011, 17, 320–329. [Google Scholar] [CrossRef] [PubMed]
- Witsch, E.; Sela, M.; Yarden, Y. Roles for growth factors in cancer progression. Physiology 2010, 25, 85–101. [Google Scholar] [CrossRef] [PubMed]
- Zhong, X.-Y.; Ding, J.-H.; Adams, J.A.; Ghosh, G.; Fu, X.-D. Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes Dev. 2009, 23, 482–495. [Google Scholar] [CrossRef] [PubMed]
- Munoz, U.; Puche, J.E.; Hannivoort, R.; Lang, U.E.; Cohen-Naftaly, M.; Friedman, S.L. Hepatocyte growth factor enhances alternative splicing of the Krüppel-like Factor 6 (KLF6) tumor suppressor to promote growth through SRSF1. Mol. Cancer Res. 2012, 10, 1216–1227. [Google Scholar] [CrossRef] [PubMed]
- Horiguchi, K.; Sakamoto, K.; Koinuma, D.; Semba, K.; Inoue, A.; Inoue, S.; Fujii, H.; Yamaguchi, A.; Miyazawa, K.; Miyazono, K.; et al. TGF-β drives epithelial-mesenchymal transition through δEF1-mediated downregulation of ESRP. Oncogene 2012, 31, 3190–3201. [Google Scholar] [CrossRef] [PubMed]
- Warzecha, C.C.; Jiang, P.; Amirikian, K.; Dittmar, K.A.; Lu, H.; Shen, S.; Guo, W.; Xing, Y.; Carstens, R.P. An ESRP-regulated splicing programme is abrogated during the epithelial–mesenchymal transition. EMBO J. 2010, 29, 3286–3300. [Google Scholar] [CrossRef] [PubMed]
- Ishii, H.; Saitoh, M.; Sakamoto, K.; Kondo, T.; Katoh, R.; Tanaka, S.; Motizuki, M.; Masuyama, K.; Miyazawa, K. Epithelial Splicing Regulatory Proteins 1 (ESRP1) and 2 (ESRP2) suppress cancer cell motility via different mechanisms. J. Biol. Chem. 2014, 289, 27386–27399. [Google Scholar] [CrossRef] [PubMed]
- Chandra, M.; Zang, S.; Li, H.; Zimmerman, L.J.; Champer, J.; Tsuyada, A.; Chow, A.; Zhou, W.; Yu, Y.; Gao, H.; et al. Nuclear translocation of type I transforming growth factor receptor confers a novel function in RNA processing. Mol. Cell Biol. 2012, 32, 2183–2195. [Google Scholar] [CrossRef] [PubMed]
- Nowak, D.G.; Amin, E.M.; Rennel, E.S.; Hoareau-Aveilla, C.; Gammons, M.; Damodoran, G.; Hagiwara, M.; Harper, S.J.; Woolard, J.; Ladomery, M.R.; et al. Regulation of vascular endothelial growth factor (VEGF) splicing from pro-angiogenic to anti-angiogenic isoforms: A novel therapeutic strategy for angiogenesis. J. Biol. Chem. 2010, 285, 5532–5540. [Google Scholar] [CrossRef] [PubMed]
- Malakar, P.; Chartarifsky, L.; Hija, A.; Leibowitz, G.; Glaser, B.; Dor, Y.; Karni, R. Insulin receptor alternative splicing is regulated by insulin signaling and modulates beta cell survival. Sci. Rep. 2016, 6, 31222. [Google Scholar] [CrossRef] [PubMed]
- Patel, N.A.; Chalfant, C.E.; Watson, J.E.; Wyatt, J.R.; Dean, N.M.; Eichler, D.C.; Cooper, D.R. Insulin regulates alternative splicing of protein kinase C βII through a phosphatidylinositol 3-Kinase-dependent pathway involving the nuclear serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells. J. Biol. Chem. 2001, 276, 22648–22654. [Google Scholar] [CrossRef] [PubMed]
- Bonomi, S.; di Matteo, A.; Buratti, E.; Cabianca, D.S.; Baralle, F.E.; Ghigna, C.; Biamonti, G. HnRNP A1 controls a splicing regulatory circuit promoting mesenchymal-to-epithelial transition. Nucleic Acids Res. 2013, 41, 8665–8679. [Google Scholar] [CrossRef] [PubMed]
- Biamonti, G.; Bonomi, S.; Gallo, S.; Ghigna, C. Making alternative splicing decisions during epithelial-to-mesenchymal transition (EMT). Cell. Mol. Life Sci. 2012, 69, 2515–2526. [Google Scholar] [CrossRef] [PubMed]
- Dery, K.J.; Kujawski, M.; Grunert, D.; Wu, X.; Ngyuen, T.; Cheung, C.; Yim, J.H.; Shively, J.E. IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform. Mol. Cancer 2014, 13, 64. [Google Scholar] [CrossRef] [PubMed]
- Ortis, F.; Naamane, N.; Flamez, D.; Ladriere, L.; Moore, F.; Cunha, D.A.; Colli, M.L.; Thykjaer, T.; Thorsen, K.; Orntoft, T.F.; et al. Cytokines Interleukin-1 and tumor necrosis factor- regulate different transcriptional and alternative splicing networks in primary cells. Diabetes 2010, 59, 358–374. [Google Scholar] [CrossRef] [PubMed]
- Li, C.Y.; Chu, J.Y.; Yu, J.K.; Huang, X.Q.; Liu, X.J.; Shi, L.; Che, Y.C.; Xie, J.Y. Regulation of alternative splicing of Bcl-x by IL-6, GM-CSF and TPA. Cell Res. 2004, 14, 473–479. [Google Scholar] [CrossRef] [PubMed]
- Eissa, N.T.; Strauss, A.J.; Haggerty, C.M.; Choo, E.K.; Chu, S.C.; Moss, J. Alternative splicing of human inducible nitric-oxide synthase mRNA: Tissue-specific regulation and induction by cytokines. J. Biol. Chem. 1996, 271, 27184–27187. [Google Scholar] [CrossRef] [PubMed]
- Matos, P.; Kotelevets, L.; Goncalves, V.; Henriques, A.; Zerbib, P.; Moyer, M.P.; Chastre, E.; Jordan, P. Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b. Neoplasia 2013, 15, 102–111. [Google Scholar] [CrossRef] [PubMed]
- Goncalves, V.; Matos, P.; Jordan, P. Ibuprofen downregulates alternative splicing of RAC1b in colorectal tumor cells through a SRPK1/SRSF1 axis. Manuscript in preparation.
- Semenza, G.L. HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations. J. Clin. Investig. 2013, 123, 3664–3671. [Google Scholar] [CrossRef] [PubMed]
- Sena, J.A.; Wang, L.; Heasley, L.E.; Hu, C.-J. Hypoxia regulates alternative splicing of HIF and non-HIF target genes. Mol. Cancer Res. 2014, 12, 1233–1243. [Google Scholar] [CrossRef] [PubMed]
- Jakubauskiene, E.; Vilys, L.; Makino, Y.; Poellinger, L.; Kanopka, A. Increased serine-arginine (SR) protein phosphorylation changes Pre-mRNA splicing in hypoxia. J. Biol. Chem. 2015, 290, 18079–18089. [Google Scholar] [CrossRef] [PubMed]
- Prasad, S.; Gupta, S.C.; Pandey, M.K.; Tyagi, A.K.; Deb, L. Oxidative Stress and Cancer: Advances and Challenges. Oxidative Med. Cell. Longev. 2016, 2016, 5010423. [Google Scholar] [CrossRef] [PubMed]
- Takeo, K.; Kawai, T.; Nishida, K.; Masuda, K.; Teshima-Kondo, S.; Tanahashi, T.; Rokutan, K. Oxidative stress-induced alternative splicing of transformer 2beta (SFRS10) and CD44 pre-mRNAs in gastric epithelial cells. AJP Cell Physiol. 2009, 297, C330–C338. [Google Scholar] [CrossRef] [PubMed]
- Allemand, E.; Guil, S.; Myers, M.; Moscat, J.; Caceres, J.F.; Krainer, A.R. Regulation of heterogenous nuclear ribonucleoprotein A1 transport by phosphorylation in cells stressed by osmotic shock. Proc. Natl. Acad. Sci. USA 2005, 102, 3605–3610. [Google Scholar] [CrossRef] [PubMed]
- Guil, S.; Long, J.C.; Caceres, J.F. HnRNP A1 Relocalization to the stress granules reflects a role in the stress response. Mol. Cell. Biol. 2006, 26, 5744–5758. [Google Scholar] [CrossRef] [PubMed]
- Van der Houven van Oordt, W.; Diaz-Meco, M.T.; Lozano, J.; Krainer, A.R.; Moscat, J.; Cáceres, J.F. The MKK(3/6)-p38-signaling cascade alters the subcellular distribution of hnRNP A1 and modulates alternative splicing regulation. J. Cell Biol. 2000, 149, 307–316. [Google Scholar] [CrossRef] [PubMed]
- Jacob, A.G.; Singh, R.K.; Comiskey, D.F.; Rouhier, M.F.; Mohammad, F.; Bebee, T.W.; Chandler, D.S. Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-Pathway in distinct ways. PLoS ONE 2014, 9, e104444. [Google Scholar] [CrossRef] [PubMed]
- Edmond, V.; Moysan, E.; Khochbin, S.; Matthias, P.; Brambilla, C.; Brambilla, E.; Gazzeri, S.; Eymin, B. Acetylation and phosphorylation of SRSF2 control cell fate decision in response to cisplatin: Acetylation controls SRSF2 protein level. EMBO J. 2011, 30, 510–523. [Google Scholar] [CrossRef] [PubMed]
- Himeji, D. Characterization of caspase-8L: A novel isoform of caspase-8 that behaves as an inhibitor of the caspase cascade. Blood 2002, 99, 4070–4078. [Google Scholar] [CrossRef] [PubMed]
- Muñoz, M.J.; Nieto Moreno, N.; Giono, L.E.; Cambindo Botto, A.E.; Dujardin, G.; Bastianello, G.; Lavore, S.; Torres-Méndez, A.; Menck, C.F.M.; Blencowe, B.J.; et al. Major roles for pyrimidine dimers, nucleotide excision repair, and ATR in the alternative splicing response to UV irradiation. Cell Rep. 2017, 18, 2868–2879. [Google Scholar] [CrossRef] [PubMed]
- Leight, J.L.; Drain, A.P.; Weaver, V.M. Extracellular matrix remodeling and stiffening modulate tumor phenotype and treatment response. Annu. Rev. Cancer Biol. 2017, 1, 313–334. [Google Scholar] [CrossRef]
- Lu, P.; Weaver, V.M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol. 2012, 196, 395–406. [Google Scholar] [CrossRef] [PubMed]
- Rubashkin, M.G.; Ou, G.; Weaver, V.M. Deconstructing signaling in three dimensions. Biochemistry 2014, 53, 2078–2090. [Google Scholar] [CrossRef] [PubMed]
- Pelisch, F.; Blaustein, M.; Kornblihtt, A.R.; Srebrow, A. Cross-talk between signaling pathways regulates alternative splicing: A novel role for JNK. J. Biol. Chem. 2005, 280, 25461–25469. [Google Scholar] [CrossRef] [PubMed]
- Bordeleau, F.; Califano, J.P.; Negrón Abril, Y.L.; Mason, B.N.; LaValley, D.J.; Shin, S.J.; Weiss, R.S.; Reinhart-King, C.A. Tissue stiffness regulates serine/arginine-rich protein-mediated splicing of the extra domain B-fibronectin isoform in tumors. Proc. Natl. Acad. Sci. USA 2015, 112, 8314–8319. [Google Scholar] [CrossRef] [PubMed]
- Pelisch, F.; Khauv, D.; Risso, G.; Stallings-Mann, M.; Blaustein, M.; Quadrana, L.; Radisky, D.C.; Srebrow, A. Involvement of hnRNP A1 in the matrix metalloprotease-3-dependent regulation of Rac1 pre-mRNA splicing. J. Cell. Biochem. 2012, 113, 2319–2329. [Google Scholar] [CrossRef] [PubMed]
- Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.; Albertson, D.G.; Nieto, M.A.; et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436, 123–127. [Google Scholar] [CrossRef] [PubMed]
- Convertini, P.; Shen, M.; Potter, P.M.; Palacios, G.; Lagisetti, C.; de la Grange, P.; Horbinski, C.; Fondufe-Mittendorf, Y.N.; Webb, T.R.; Stamm, S. Sudemycin E influences alternative splicing and changes chromatin modifications. Nucleic Acids Res. 2014, 42, 4947–4961. [Google Scholar] [CrossRef] [PubMed]
- Xargay-Torrent, S.; López-Guerra, M.; Rosich, L.; Montraveta, A.; Roldán, J.; Rodríguez, V.; Villamor, N.; Aymerich, M.; Lagisetti, C.; Webb, T.R.; et al. The splicing modulator sudemycin induces a specific antitumor response and cooperates with ibrutinib in chronic lymphocytic leukemia. Oncotarget 2015, 6, 22734–22749. [Google Scholar] [CrossRef] [PubMed]
- Pandit, S.; Zhou, Y.; Shiue, L.; Coutinho-Mansfield, G.; Li, H.; Qiu, J.; Huang, J.; Yeo, G.W.; Ares, M.; Fu, X.-D. Genome-wide analysis reveals SR protein cooperation and competition in regulated splicing. Mol. Cell 2013, 50, 223–235. [Google Scholar] [CrossRef] [PubMed]
- Barbosa-Morais, N.L.; Carmo-Fonseca, M.; Aparício, S. Systematic genome-wide annotation of spliceosomal proteins reveals differential gene family expansion. Genome Res. 2005, 16, 66–77. [Google Scholar] [CrossRef] [PubMed]
- Castello, A.; Fischer, B.; Eichelbaum, K.; Horos, R.; Beckmann, B.M.; Strein, C.; Davey, N.E.; Humphreys, D.T.; Preiss, T.; Steinmetz, L.M.; et al. Insights into RNA biology from an atlas of mammalian mRNA-binding proteins. Cell 2012, 149, 1393–1406. [Google Scholar] [CrossRef] [PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gonçalves, V.; Pereira, J.F.S.; Jordan, P. Signaling Pathways Driving Aberrant Splicing in Cancer Cells. Genes 2018, 9, 9. https://doi.org/10.3390/genes9010009
Gonçalves V, Pereira JFS, Jordan P. Signaling Pathways Driving Aberrant Splicing in Cancer Cells. Genes. 2018; 9(1):9. https://doi.org/10.3390/genes9010009
Chicago/Turabian StyleGonçalves, Vânia, Joana F. S. Pereira, and Peter Jordan. 2018. "Signaling Pathways Driving Aberrant Splicing in Cancer Cells" Genes 9, no. 1: 9. https://doi.org/10.3390/genes9010009